Q32 Bio (QTTB) Expected to Announce Quarterly Earnings on Tuesday

Q32 Bio (NASDAQ:QTTB) is projected to release its Q4 2025 results before the market opens on Tuesday, March 10th. Analysts expect Q32 Bio to post earnings of ($1.06) per share for the quarter. Parties may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Wednesday, March 18, 2026 at 12:30 PM ET.

Q32 Bio Stock Performance

Shares of QTTB opened at $4.70 on Monday. Q32 Bio has a fifty-two week low of $1.35 and a fifty-two week high of $6.37. The company has a market capitalization of $57.81 million, a price-to-earnings ratio of -1.37 and a beta of 0.14. The firm has a 50-day simple moving average of $3.98 and a 200-day simple moving average of $3.01.

Analyst Upgrades and Downgrades

Several analysts have commented on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Q32 Bio in a research note on Friday, January 9th. HC Wainwright assumed coverage on Q32 Bio in a research note on Wednesday, February 25th. They issued a “buy” rating and a $13.00 target price on the stock. One research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Q32 Bio currently has a consensus rating of “Hold” and an average price target of $14.00.

Insider Activity

In related news, CEO Jodie Pope Morrison sold 9,896 shares of the stock in a transaction dated Wednesday, February 25th. The shares were sold at an average price of $4.51, for a total transaction of $44,630.96. Following the completion of the transaction, the chief executive officer directly owned 89,104 shares of the company’s stock, valued at $401,859.04. This represents a 10.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. Insiders have sold 16,706 shares of company stock worth $75,344 in the last quarter. Insiders own 40.00% of the company’s stock.

Hedge Funds Weigh In On Q32 Bio

A number of large investors have recently modified their holdings of QTTB. HRT Financial LP boosted its stake in shares of Q32 Bio by 66.5% in the fourth quarter. HRT Financial LP now owns 24,698 shares of the company’s stock valued at $81,000 after buying an additional 9,862 shares in the last quarter. Acadian Asset Management LLC acquired a new position in Q32 Bio during the first quarter worth $50,000. XTX Topco Ltd purchased a new position in Q32 Bio in the fourth quarter worth $68,000. Jane Street Group LLC purchased a new position in Q32 Bio in the second quarter worth $69,000. Finally, Goldman Sachs Group Inc. lifted its holdings in Q32 Bio by 140.9% in the first quarter. Goldman Sachs Group Inc. now owns 44,373 shares of the company’s stock valued at $73,000 after acquiring an additional 25,953 shares during the period. 31.32% of the stock is owned by hedge funds and other institutional investors.

Q32 Bio Company Profile

Q32 Bio Inc, a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis.